🚨 #ESMO26 Lung Cancer: the 10 studies that best capture where the field is moving
@OncoAlert
What stands out to me from the @OncoAlert faculty selection is how much the lung cancer landscape is shifting toward smarter sequencing, biomarker-defined combinations, and more selective treatment intensification.

🫁 Top Ten from Madrid:

1️⃣ DeLLphi-305 — tarlatamab + durvalumab in 1L ES-SCLC maintenance
2️⃣ Krascendo 1 — divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON — osimertinib + savolitinib after osimertinib in EGFRm/MET+ disease
4️⃣ OptiTROP-Lung04 — sac-TMT after EGFR-TKI
5️⃣ OptiTROP-Lung06 — sac-TMT + pembrolizumab in PD-L1-negative NSCLC
6️⃣ PERSEE — pembrolizumab ± chemotherapy in PD-L1 ≥50%
7️⃣ SANOVO — savolitinib + osimertinib in 1L EGFRm/MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL — continue pembrolizumab vs observation at 6 months
9️⃣ PANKU-Lung01 — iza-bren after third-generation EGFR TKI
🔟 SARON — consolidation RT in oligometastatic NSCLC

🎯 Why this matters: these studies are not just adding new drugs. They are refining when to intensify, when to combine, when to continue, and when biology should drive the next step.

That is the real value of a “Top Ten” list: not more information — better prioritization of the data most likely to influence practice.

@christine_lovly @GlopesMd @DrSanjayPopat @StephenVLiu @jillfeldman4 @UOzkerim @DrMirallas @CharuAggarwalMD @peters_solange @JordiRemon

#lcsm #OncoAlert #ESMO26 #LungCancer #NSCLC #SCLC #PrecisionOncology